Subscribe

0

  • Sign in with Email

By clicking the button, I accept the Terms of Use of the service and its Privacy Policy, as well as consent to the processing of personal data.

Don’t have an account? Signup

  • Bookmarks
  • My Profile
  • Log Out
  • NEWS
  • POLICIES
  • MSME OPPORTUNITIES
  • BANKING & FINANCE
  • TECHNOLOGY FOR SMES
  • SECTORS
  • GLOBAL
  • Investment
  • LEGAL
  • KNOWLEDGE QUEST
  • Future Ready Forum 2025
  • Ek Nayi Udaan
  • Future Ready Summit 2024
  • ADVERTISE WITH US
ad_close_btn
  • News
  • Policies
  • Banking & Finance
  • MSME Opportunities
  • Web Stories
  • InFocus
  • Technology For SMEs
  • Sectors
  • Global
  • Fashion

Powered by :

You have successfully subscribed the newsletter.

DCGI

Progress on COVID vaccine, SMESTreet LimeLight

DCGI Approves Phase II/III Clinical Trial of COVAXIN Among Age Group of 2 to 18 Years

Bharat Biotech International Ltd., Hyderabad (BBIL) had proposed to carry out a Phase- II/III clinical trial of Covaxin in the age group of 2 to 18 years. The trial will be conducted in 525 healthy volunteers.

By SMEStreet Edit Desk
logoMay 13, 2021 10:36 IST logo 1 Min read
VG Somani, DCGI, Drug controller general of India News
DGCI Gave Approvals To Serum Institute for Clinical Trials of Oxford COVID-19 Vaccine
By SMEStreet Edit Desk
logoSep 16, 2020 04:27 IST logo 2 Min read
VG Somani, DCGI, Drug controller general of India News
DCGI Grants Approval for Pneumococcal Polysaccharide Conjugate Vaccine to Serum Institute
By SMEStreet Edit Desk
logoJul 15, 2020 11:02 IST logo 1 Min read
Made in India Favipiravir, Biophore, DCGI, SMEStreet LimeLight
Biophore Claims the Validation for Scaled Up Production of Made-In-India Favipiravir for Covid-19
By SMEStreet Desk
logoJul 14, 2020 06:02 IST logo 2 Min read
newsletter image
Subscribe to our Newsletter! Be the first to get exclusive offers and the latest news
Latest Stories
Subscribe to our Newsletter! Be the first to get exclusive offers and the latest news

Latest Stories
Latest Stories
    Powered by


    Subscribe to our Newsletter!




    Powered by
    Select Language
    English

    Share this article

    If you liked this article share it with your friends.
    they will thank you later

    Facebook
    Twitter
    Whatsapp

    Copied!